Lenzing, Balances

Lenzing Balances EUR 136 Million Impairment Against a EUR 50 Million Nonwovens Push

Published on 11/17/2026 at 11:20 | Editorial boerse-global.de
Lenzing's nine-month report shows EUR 130.3 million net loss on impairments, while the fibre maker invests EUR 27 million in Alabama nonwovens capacity.
Lenzing Balances EUR 136 Million Impairment Against a EUR 50 Million Nonwovens Push Illustration mit AI erstellt.

Lenzing's nine-month report, released on 5 November, tells two stories at once. One is a balance sheet dented by write-downs and restructuring charges; the other is a fibre specialist still committing fresh capital to its specialty nonwovens business. For investors, the trick is holding both in view without letting either one crowd out the other.

Revenue for the first nine months of 2026 came in at EUR 1.93 billion. Adjusted EBITDA reached EUR 353 million, a figure that translates into an 18.3 percent adjusted margin on the company's own numbers. Strip out the adjustments and the picture darkens: unadjusted EBITDA was EUR 316.4 million, dragged down by EUR 36.6 million in restructuring effects.

Write-downs Push the Bottom Line Into the Red

The heaviest blow landed below the operating line. Impairments of EUR 136.1 million on the Heiligenkreuz and Grimsby sites pushed earnings before interest and taxes to a loss of EUR 55.1 million. The net loss after tax came to EUR 130.3 million, according to ORF.

Neither earnings measure deserves to be treated as the whole truth. Adjusted EBITDA shows what the underlying business can earn once special items are set aside; the unadjusted figure and the net result show what the restructuring actually costs. Leaning only on the first risks an overly generous reading. Fixating on the charges alone ignores the earning power Lenzing does report.

Should investors sell immediately? Or is it worth buying Lenzing?

Heiligenkreuz: Bids on the Table, Deadline in Sight

The site question sits at the centre of that tension. Last week Lenzing disclosed several non-binding purchase offers for its Heiligenkreuz plant and said it is evaluating which interested parties to continue the sale process with. A decision is due by the end of the year: either a viable sale materialises, or the site closes at the end of the first quarter of 2027. The word "non-binding" matters here — interest in a plant is not a completed transaction, and it would be premature to book it as relief.

Alabama Expansion Proceeds Alongside the Cuts

On the investment side, Lenzing announced EUR 27 million for its Mobile, Alabama site last week. That spending expands specialty fibre capacity for nonwoven applications and forms part of a EUR 50 million programme for the nonwovens business, alongside a previously announced EUR 23 million investment at the Lenzing site. The outlay sits side by side with the restructuring charges rather than contradicting them — evidence that Lenzing is not a straightforward cost-cutting story.

An investment announcement, though, is not proof of the earnings contribution those outlays will eventually deliver. Management flags a volatile market environment, geopolitical tensions and uncertainty over trade policy, compounded by persistently elevated energy and chemical costs. Those are the conditions under which every operating and capital decision is being made.

Lenzing at a turning point? This analysis reveals what investors need to know now.

What to Watch Before the 2027 Guidance Point

The next scheduled checkpoint is the full-year 2026 results on 18 March 2027. Until then, the nine-month figures set the framework: acknowledge the adjusted earning power, take the restructuring charges seriously, and don't confuse announced measures with results already achieved. How well Lenzing executes its restructuring — not any single metric — is the story that matters.

The stock slipped 3.1 percent on the day of the report, following a 2.0 percent decline in the prior session.

Ad

Lenzing Stock: New Analysis - 17 November

Fresh Lenzing information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Lenzing analysis...

Disclaimer...
en | AT0000644505 | LENZING | boerse | 70526053 |